Moderna said Tuesday its coronavirus vaccine strongly protects children as young as 12 years, a step that could put the shot on track to become the second option for that age group in the U.S, AP reports.
With global vaccine supplies still tight, much of the world is struggling to vaccinate adults in the quest to end the pandemic. But earlier this month, the U.S. and Canada authorized another vaccine — the shot made by Pfizer and BioNTech — to be used starting at age 12.
Moderna aims to be next in line, saying it will submit its teen data to the U.S. Food and Drug Administration and other global regulators early next month.
The company studied more than 3,700 12- to 17-year-olds. Preliminary findings showed the vaccine triggered the same signs of immune protection in kids as it does in adults, and the same kind of temporary side effects such as sore arms, headache and fatigue.
There were no coronavirus disease diagnoses in those given two doses of the Moderna vaccine compared with four among children given dummy shots. In a press release, the company also said the vaccine appeared 93 percent effective two weeks after the first dose.